Skip to Content
Merck
  • A detailed examination of platelet function inhibition by nitric oxide in platelet-rich plasma and whole blood.

A detailed examination of platelet function inhibition by nitric oxide in platelet-rich plasma and whole blood.

Clinical laboratory (2013-07-20)
Robert Zimmermann, Julia Krueger, Milos R Filipović, Ivana Ivanović-Burmazović, Andreas Calatzis, Dominik R Weiss, Reinhold Eckstein
ABSTRACT

The question of whether novel instruments such as multiple electrode aggregometry (MEA) can be used for measurement of the effects of nitric oxide (NO) on platelets (PLTs) has not been examined. Therefore, we compared the effects of NO concentrations (1, 10, and 100 microM) on the PLT aggregation response to ADP, arachidonic acid (AA), collagen, ristocetin, and thrombin receptor-activating peptide 6 (TRAP6) using light transmission aggregometry (LTA) and multiple electrode aggregometry (MEA) and examined the effects of NO using the platelet function analyzer (PFA)-100. The response of PLTs to ADP and AA was strongly inhibited by all NO concentrations in LTA and MEA. The inhibition of the responses to ristocetin and collagen was detectable in MEA at lower NO concentrations than in LTA. However, the typically increasing lag phase between collagen addition and the aggregation response in the presence of NO was more obvious in LTA. TRAP caused a reproducible early response in the presence of NO in LTA which was followed by rapid PLT disaggregation, whereas even 100 microM NO did not inhibit the response to TRAP in MEA. Finally, NO prolonged the in-vitro bleeding time remarkably more in the PFA-100 collagen-epinephrin cartridge than in the collagen-ADP cartridge. Whole blood versus PLT rich plasma, citrate versus hirudin, and high versus low shear influenced the effects of NO. This shows that a careful selection of models and potentially a combination of different methods is appropriate for a differentiated evaluation of pharmacological or physiological mechanisms of NO-donors or of NO-inhibitors.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Collagen from rabbit skin, Bornstein and Traub Type I, powder
Sigma-Aldrich
Collagen from bovine tracheal cartilage, Bornstein and Traub Type II, powder
Sigma-Aldrich
Collagen from rat tail, Bornstein and Traub Type I, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Collagen from bovine nasal septum, Bornstein and Traub Type II, powder
Sigma-Aldrich
Collagen from Engelbreth-Holm-Swarm murine sarcoma basement membrane, Type IV (Miller), lyophilized powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Collagen from human placenta, Bornstein and Traub Type III (Sigma Type X), powder
Sigma-Aldrich
Collagen Type IV from human cell culture, Bornstein and Traub Type IV, 0.3 mg/mL, sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
Collagen human, Bornstein and Traub Type I, acid soluble, powder, ~95% (SDS-PAGE)
Sigma-Aldrich
Collagen from calf skin, Bornstein and Traub Type I, solid, BioReagent, suitable for cell culture
Sigma-Aldrich
Collagen from calf skin, Bornstein and Traub Type I, (0.1% solution in 0.1 M acetic acid), aseptically processed, BioReagent, suitable for cell culture
Sigma-Aldrich
Collagen from human placenta, Bornstein and Traub Type V (Sigma Type IX), powder
Sigma-Aldrich
Collagen from human placenta, Bornstein and Traub Type IV, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Collagen from bovine achilles tendon, powder, suitable for substrate for collagenase
Sigma-Aldrich
Collagen from human placenta, Bornstein and Traub Type I (Sigma Type VIII), powder
Sigma-Aldrich
Collagen from human placenta, Bornstein and Traub Type IV, powder
Sigma-Aldrich
Collagen from chicken sternal cartilage, Type II (Miller), powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Collagen from human placenta, Bornstein and Traub Type IV, solution, suitable for cell culture, High Performance
Sigma-Aldrich
Collagen from human placenta, Bornstein and Traub Type IV, powder